title: Why is there so much therapy-related AML and MDS and so little therapy-related CML?
authors.affiliation: Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK. Electronic address: robertpetergale@gmail.com.
authors.forename: Robert Peter
authors.initials: RP
authors.lastname: Gale
authors.affiliation: Center of Cancer Systems Biology, GRI, Tufts University School of Medicine, Boston, MA, United States.
authors.forename: Lynn
authors.initials: L
authors.lastname: Hlatky
authors.affiliation: Department of Mathematics and Physics, University of California, Berkeley, CA, United States.
authors.forename: Rainer K
authors.initials: RK
authors.lastname: Sachs
authors.affiliation: Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, United States.
authors.forename: Tomas
authors.initials: T
authors.lastname: Radivoyevitch
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000453:epidemiology* / Q000235:genetics; D015470:Leukemia, Myeloid, Acute / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics; D007953:Leukemia, Radiation-Induced / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics; D009190:Myelodysplastic Syndromes / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000453:epidemiology / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents
keywords: DNA-damaging drugs; Radiation; Secondary leukemia; Therapy-related leukemia